Abstract
Due in part to the dramatic increase in virally mediated cancers, the demographic landscape of head and neck cancer (HNCa) is rapidly changing. While the incidence of HNCa has declined at various anatomic subsites, this downward trend is masked by unbridled growth in the number of oropharyngeal squamous cell cancers (OPSCCs). The climbing incidence of OPSCCs is fueled by a dramatic rise in human papillomavirus (HPV)-related cancers, which are now recognized as a distinct disease entity.
At present, treatment practices for HNCa are selected based on disease- and patient-related factors. However, the emergence of HPV-related disease has led to renewed focus on biology-driven treatment approaches. In order to provide information regarding disease progression and prognosis, and disease- and treatment-related effects on function and quality of life to patients treated for HNCa, clinicians must be cognizant of the critical differences associated with virally mediated disease.
This chapter will provide information regarding the role of human papillomavirus (HPV) in carcinogenesis, its impact on the clinical and morphological features of HNCa, and implications for patient functioning and quality of life.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Notes
- 1.
For a comprehensive review of the numerous and complex molecular drivers of carcinogenesis that differentiate HPV-positive versus HPV-negative disease, see Gillison (2004).
- 2.
The main premise of treatment de-escalation is that a reduction in treatment intensity is likely to be accompanied by a reduction in morbidity associated with standard treatment protocols. For a comprehensive review of recent and ongoing de-escalation trials, see Masterson et al. (2014).
References
Adelstein, D., Gillison, M. L., Pfister, D. G., Spencer, S., Adkins, D., Brizel, D. M., et al. (2017). NCCN guidelines insights: Head and neck cancers, version 2.2017. Journal of the National Comprehensive Cancer Network: JNCCN, 15(6), 761–770.
Agrawal, N., Frederick, M. J., Pickering, C. R., Bettegowda, C., Chang, K., Li, R. J., et al. (2011). Exome sequencing of head and neck squamous cell carcinomas reveals inactivating mutations in NOTCH1. Science, 333(6046), 1154–1157.
American Cancer Society. (2016). Cancer facts & figures 2016. Atlanta, GA: American Cancer Society; 2016. Retrieved October 6, 2017 from https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2016/cancer-facts-and-figures-2016.pdf
American Joint Committee on Cancer. (2017a). Retrieved September 25, 2017, from https://cancerstaging.org/references-tools/Pages/What-is-Cancer-Staging.aspx
American Joint Committee on Cancer. (2017b). Retrieved August 14, 2017, from https://cancerstaging.org/About/news/Pages/Implementation-of-AJCC-8th-Edition-Cancer-Staging-System.aspx
Ang, K. K., Harris, J., Wheeler, R., Weber, R., Rosenthal, D. I., Nguyen-Tan, P. F., et al. (2010). Human papillomavirus and survival of patients with oropharyngeal cancer. New England Journal of Medicine, 363, 24–35.
Arbyn, M., de Sanjose, S., Saraiya, M., Sideri, M., Palefsky, J., Lacey, C., et al. (2012). EUROGIN 2011 roadmap on prevention and treatment of HPV-related disease. International Journal of Cancer, 131(9), 1969–1982.
Argiris, A., Li, S., Ghebremichael, M., Egloff, A. M., Wang, L., Forastiere, A. A., et al. (2014). Prognostic significance of human papillomavirus in recurrent or metastatic head and neck cancer: An analysis of eastern cooperative oncology group trials. Annals of Oncology, 25, 1210–1216.
Barnoya, J., & Glantz, S. (2004). Association of the California tobacco control program with declines in lung cancer incidence. Cancer Causes & Control, 15(7), 689–695.
Baxi, S. S., Shuman, A. G., Corner, G. W., Shuk, E., Sherman, E. J., Elkin, E. B., et al. (2013). Sharing a diagnosis of HPV-related head and neck cancer: The emotions, the confusion and what patients want to know. Head & Neck, 35(11), 1534–1541.
Blanchard, P., Baujat, B., Holostenco, V., Bourredjem, A., Baey, C., Bourhis, J., et al. (2011). Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): A comprehensive analysis by tumour site. Radiotherapy & Oncology, 100(1), 33–40.
Bledsoe, T. J., Noble, A. R., Hunter, G. K., Rybicki, L. A., Hoschar, A., Chute, D. J., et al. (2013). Oropharyngeal squamous cell carcinoma with known human papillomavirus status treated with definitive chemoradiotherapy: Patterns of failure and toxicity outcomes. Radiation Oncology, 8, 174.
Bonner, J. A., Harari, P. M., Giralt, J., Azarnia, N., Shin, D. M., Cohen, R. B., … Ang, K. K. (2006). Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. New England Journal of Medicine, 354(6), 567–578.
Bornbaum, C. C., Doyle, P. C., Skarakis-Doyle, E., & Theurer, J. A. (2013). A critical exploration of the International Classification of Functioning, Disability, and Health (ICF) framework from the perspective of oncology: Recommendations for revision. Journal of Multidisciplinary Healthcare, 6, 75–86.
Bornbaum, C. C., Fung, K., Franklin, J. H., Nichols, A., Yoo, J., & Doyle, P. (2012). A descriptive analysis of the relationship between quality of life and distress in individuals with head and neck cancer. Supportive Care in Cancer, 20(9), 2157–2165.
Bourhis, J., Overgaard, J., Audry, H., Ang, K. K., Saunders, M., Bernier, J., et al. (2006). Hyperfractionated or accelerated radiotherapy in head and neck cancer: A meta-analysis. Lancet, 368(9538), 843–854.
Brizel, D. M., Albers, M. E., Fisher, S. R., Scher, R. L., Richtsmeier, W. J., Hars, V., et al. (1998). Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. New England Journal of Medicine, 338(25), 1798–1804.
Brown, D. R., Schroeder, J. M., Bryan, J. T., et al. (1999). Detection of multiple human papillomavirus types in condylomata acuminate lesions from other healthy and immunosuppressed patients. Journal of Clinical Microbiology, 37, 3316–3322.
Canadian Cancer Society. (2016a). Retrieved on August 16, 2017 from http://www.cancer.ca/en/cancer-information/cancer-101/canadian-cancer-statistics-publication/canadian-cancer-statistics-infographics/?region=on.
Canadian Cancer Society. (2016b). Canadian cancer statistics 2016. Special topic: HPV-associated cancers. Retrieved August 16, 2017 from http://www.cancer.ca/~/media/cancer.ca/CW/cancer%20information/cancer%20101/Canadian%20cancer%20statistics/Canadian-Cancer-Statistics-2016-EN.pdf?la=en.
Centers for Disease Control and Prevention (CDC). (2011). Vital signs: Current cigarette smoking among adults aged ≥ 18 years – United States, 2005-2010. Morbidity and Mortality Weekly Report, 60, 1207–1211.
Centers for Disease Control and Prevention, National Center for Health Statistics. (n.d.). About the National Health and Nutrition Examination Survey. Retrieved August 17, 2017, from http://www.cdc.gov/nchs/nhanes/about_nhanes.htm
Chaturvedi, A. K., Anderson, W. F., Lortet-Tieulent, J., Curado, M. P., Ferlay, J., Franceschi, S., et al. (2013). Worldwide trends in incidence rates for oral cavity and oropharyngeal cancers. Journal of Clinical Oncology, 31, 4550–4559.
Chaturvedi, A. K., D’Souza, G., Gillison, M. L., & Katki, H. A. (2016). Burden of HPV-positive oropharynx cancers among ever and never smokers in the U.S. population. Oral Oncology, 60, 61–67.
Chaturvedi, A. K., Engels, E. A., Pfeiffer, R. M., Hernandez, B. Y., Xiao, W., Kim, E., et al. (2011). Human papillomavirus and rising oropharyngeal cancer incidence in the United States. Journal of Clinical Oncology, 29(32), 4294–4301.
Chaturvedi, A. K., Graubard, B. I., Broutian, T., Pickard, R. K., Tong, Z. Y., Xiao, W., et al. (2015). NHANES 2009-2012 findings: Association of sexual behaviors with higher prevalence of oral oncogenic human papillomavirus infections in U.S. men. Cancer Research, 75(12), 2468–2377.
Chen, P., Yu, W., Huang, J., Xu, H., Li, G., Chen, X., et al. (2017). Matched-pair analysis of survival in patients with poorly differentiated versus well-differentiated glottis squamous cell carcinoma. Oncotarget, 8(9), 14770–14776.
Chu, A., Genden, E., Posner, M., & Sikora, A. (2013). A patient-centred approach to counselling patients with head and neck cancer undergoing human papillomavirus testing: A clinician’s guide. Oncologist, 18(2), 180–189.
Chung, C. H., & Gillison, M. L. (2009). Human papillomavirus in head and neck cancer: Its role in pathogenesis and clinical implications. Clinical Cancer Research, 15(22), 6758–6762.
D’Souza, G., & Dempsey, A. (2011). The role of HPV in head and neck cancer and review of the HPV vaccine. Preventive Medicine, 53(1 Suppl), S5–S11.
D’Souza, G., Kreimer, A. R., Viscidi, R., Pawlita, M., Fakhry, C., Koch, W. M., et al. (2007). Case-control study of human papillomavirus and oropharyngeal cancer. New England Journal of Medicine, 356(19), 1944–1956.
D’Souza, G., Wentz, A., Kluz, N., Zhang, Y., Sugar, E., Youngfellow, R. M., et al. (2016). Sex differences in risk factors and natural history of oral human papillomavirus infection. Journal of Infectious Diseases, 213(12), 1893–1896.
D’Souza, G., Zhang, Y., Merritt, S., Gold, D., Robbins, H. A., Buckman, V., et al. (2016). Patient experience and anxiety during and after treatment for an HPV-related oropharyngeal cancer. Oral Oncology, 60, 90–95.
Dahlstrom, K. R., Garden, A. S., William, W. N., Jr., Lim, M. Y., & Sturgis, E. M. (2016). Proposed staging system for patients with HPV-related oropharyngeal cancer based on nasopharyngeal cancer n categories. Journal of Clinical Oncology, 34(16), 1848–1854.
Davis, K. C., Farrelly, M. C., Duke, J., Kelly, L., & Willett, J. (2012). Antismoking media campaign and smoking cessation outcomes, New York state, 2003–2009. Preventing Chronic Diseases, 9, E40. https://doi.org/10.5888/pcd9.110102
Davis, K. S., Lim, C. M., Clump, D. A., Heron, D. E., Ohr, J. P., Kim, S., et al. (2016). Tumor volume as a predictor of survival in human papillomavirus-positive oropharyngeal cancer. Head & Neck, 38(Suppl1), 1613–1617.
De Boer, M. F., McCormick, L. K., Pruyn, J. F., Ryckman, R. M., & van den Borne, B. W. (1999). Physical and psychosocial correlates of head and neck cancer: A review of the literature. Otolaryngology – Head and Neck Surgery, 120, 427–436.
de Martel, C., Plummer, M., Vignat, J., & Franceschi, S. (2017). Worldwide burden of cancer attributable to HPV by site, country and HPV type. International Journal of Cancer, 141, 664–670.
Dodd, R. H., Marlow, L. A. V., & Waller, J. (2016). Discussing a diagnosis of human papillomavirus oropharyngeal cancer with patients: An exploratory qualitative study of health professionals. Head & Neck, 38(3), 394–401.
Dowthwaite, S. A., Franklin, J. H., Palma, D. A., Fung, K., Yoo, J., & Nichols, A. C. (2012). The role of transoral robotic surgery in the management of oropharyngeal cancer: A review of the literature. ISRN Oncology, 2012, 945162. https://doi.org/10.5402/2012/945162
Edge, S. B., Byrd, D. R., Compton, C. C., Fritz, A. G., Greene, F. L., & Trotti, A. (Eds.). (2010). AJCC cancer staging manual (7th ed.). New York, NY: Springer-Verlag.
Eisbruch, A., Lyden, T., Bradford, C. R., Dawson, L. A., Haxer, M. J., Miller, A. E., et al. (2002). Objective assessment of swallowing dysfunction and aspiration after radiation concurrent with chemotherapy for head-and-neck cancer. International Journal of Radiation Oncology, Biology, Physics, 53(1), 23–28.
El-Naggar, A. K., & Westra, W. H. (2012). p16 overexpression as a surrogate marking for HPV-related oropharyngeal carcinoma: A guide for interpretative relevance and consistency. Head & Neck, 34, 458–461.
Fakhry, C., & D’Souza, G. (2013). Discussing the diagnosis of HPV-OSCC: Common questions and answers. Oral Oncology, 49(9), 863–871.
Fakhry, C., & Gillison, M. L. (2006). Clinical implications of human papillomavirus in head and neck cancers. Journal of Clinical Oncology, 24(17), 2606–2611.
Fakhry, C., Rosenthal, B. T., Clark, D. P., & Gillison, M. L. (2011). Associations between oral HPV16 infection and cytopathology: Evaluation of an oropharyngeal “pap-test equivalent” in high-risk populations. Cancer Prevention Research, 4(9), 1378–1384.
Fakhry, C., Westra, W. H., Li, S., Cmelak, A., Ridge, J. A., Pinto, H., et al. (2008). Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. Journal of the National Cancer Institute, 100, 261–269.
Fakhry, C., Zhang, Q., Nruyen-Tan, P. F., Rosenthal, D., El-Naggar, A., Garden, A. S., et al. (2014). Human papillomavirus and overall survival after progression of oropharyngeal squamous cell carcinoma. Journal of Clinical Oncology, 32, 3365–3373.
Feller, L., Wood, N. H., Khammissa, R. A. G., & Lemmer, J. (2010). Human papillomavirus-mediated carcinogenesis and HPV-associated oral and oropharyngeal squamous cell carcinoma. Part 1: Human papillomavirus-mediated carcinogenesis. Head & Face Medicine, 6, 14–19.
Ferris, R. L., Jaffee, E. M., & Ferrone, S. (2010). Tumor antigen-targeted, monoclonal antibody-based immunotherapy: Clinical response, cellular immunity, and immunoescape. Journal of Clinical Oncology, 28, 4390–4399.
Finnigan, J. P., Jr., & Sikora, A. G. (2014). Counseling the patient with potentially HPV-related newly diagnosed head and neck cancer. Current Oncology Reports, 16(3), 375.
Franceschi, S., Munoz, N., Bosch, X. F., Snijders, P. J., & Walboomers, J. M. (1996). Human papillomavirus and cancers of the upper aerodigestive tract: A review of epidemiological and experimental evidence. Cancer Epidemiology, Biomarkers and Prevention, 5(7), 567–575.
Garcia-Piñeres, A. H., Hildesheim, A., Herrero, R., Trivett, M., Williams, M., Atmetlla, I., et al. (2006). Persistent human papillomavirus infection is associated with a generalized decreased in immune responsiveness in older women. Cancer Research, 66(22), 11070–11076.
Gasparini, R., & Panatto, D. (2009). Cervical cancer: From Hippocrates through Rigoni-Stern to zur Hausen. Vaccine, 27(1 Suppl), A4–A5.
Gillison, M. L. (2004). Human papillomavirus-associated head and neck cancer is a distinct epidemiologic, clinical, and molecular entity. Seminars in Oncology, 31(6), 744–754.
Gillison, M. L., Broutian, T., Pickard, R. K. L., Tong, Z.-Y., Xiao, W., Kahle, L., et al. (2012). Prevalence of oral HPV infection in the United States, 2009-2010. Journal of the American Medical Association, 307(7), 693–703.
Gillison, M. L., Chaturvedi, A. K., & Lowy, D. R. (2008). HPV prophylactic vaccines and the potential prevention of noncervical cancers in both men and women. Cancer, 113(10 Suppl), 3036–3046.
Gillison, M. L., D’Souza, G., Westra, W., Sugar, E., Xiao, W., Begum, S., et al. (2008). Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. Journal of the National Cancer Institute, 100, 407–420.
Gillison, M. L., Koch, W. M., Capone, R. B., Spafford, M., Westra, W. H., Wu, L., et al. (2000). Evidence for a causal association between human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. Journal of the National Cancer Institute, 92(9), 709–720.
Gillison, M. L., Zhang, Q., Jordan, R., Xiao, W., Westra, W., Trotti, A., et al. (2012). Tobacco smoking and increased risk of death and progression for patients with p16-positive and p16-negative oropharyngeal cancer. Journal of Clinical Oncology, 30, 2101–2111.
Gissman, L., Diehl, V., Schultz-Coulon, H. J., & zur Hausen, H. (1982). Molecular cloning and characterization of human papilloma virus DNA derived from a laryngeal papilloma. Journal of Virology, 44(1), 393–400.
Giuliano, A. R., Tortolero-Luna, G., Ferrer, E., Burchell, A. N., de Sanjose, S., & Kjaer, S. K. (2008). Epidemiology of human papillomavirus infection in men, cancers other than cervical and benign conditions. Vaccine, 26(Suppl 10), K17–K28.
Gooi, Z., Chan, J. Y., & Fakhry, C. (2016). The epidemiology of the human papillomavirus related to oropharyngeal head and neck cancer. Laryngoscope, 126(4), 894–900.
Habbous, S., Chu, K. P., Lau, H., Schorr, M., Belayneh, M., Ha, M. N., et al. (2017). Human papillomavirus in oropharyngeal cancer in Canada: Analysis of 5 comprehensive cancer centres using multiple imputation. Canadian Medical Association Journal, 189, E1030–E1040.
Hafkamp, H., Manni, J., Haesevoets, A., Voogd, A. C., Schepers, M., Bot, F. J., et al. (2008). Marked differences in survival rate between smokers and nonsmokers with HPV16-assocaited tonsillar carcinomas. International Journal of Cancer, 122, 2656–2664.
Hanasoge, S., Magliocca, K. R., Switchenko, J. M., Saba, N. F., Wadsworth, J. T., El-Deiry, M. W., et al. (2016). Clinical outcomes in elderly patients with human papillomavirus-positive squamous cell carcinoma of the oropharynx treated with definitive chemoradiation therapy. Head & Neck, 38(6), 846–851.
Hariri, S., Unger, E. R., Sternberg, M., Dunne, E. F., Swan, D., Patel, S., et al. (2011). Prevalence of genital human papillomavirus among females in the United States, the National Health and Nutrition Examination Survery, 2003–2006. Journal of Infectious Diseases, 204(4), 566–573.
Health Protection Agency. (2011). Trends in genital herpes and genital warts infections, United Kingdom: 2000 to 2009. Retrieved August 17, 2017, from http://webarchive.nationalarchives.gov.uk/20140714092919/, http://www.hpa.org.uk/hpr/archives/2011/hpr1711.pdf
Herrero, R., Quint, W., Hildesheim, A., Gonzalez, P., Struijk, L., Katki, H. A., et al. (2013). Reduced prevalence of oral human papillomavirus (HPV) 4 years after bivalent HPV vaccination in a randomized clinical trial in Costa Rica. PLoS One, 8(7), E68329. https://doi.org/10.1371/journal.pone.0068329
Hildesheim, A., & Herrero, R. (2007). Human papillomavirus vaccine should be given before sexual debut for maximum benefit. Journal of Infectious Diseases, 196(10), 1431–1432.
Hildesheim, A., Herrero, R., Wacholder, S., Rodriguez, A. C., Solomon, D., Bratti, M. C., et al. (2007). Effect of human papillomavirus 16/18 L1 virus like particle vaccine among young women with preexisting infection: A randomized trial. JAMA, 298(7), 743–753.
Hoffman, M., Cooper, D., Carrara, H., Rosenberg, L., Kelly, J., Stander, I., et al. (2003). Limited Pap screening associated with reduced risk of cervical cancer in South Africa. International Journal of Epidemiology, 32(4), 573–577.
Horne, Z. D., Glaser, S. M., Vargo, J. A., Ferris, R. L., Balasubramani, G. K., Clump, D. A., et al. (2016). Confirmation of proposed human papillomavirus risk-adapted staging according to AJCC/UICC TNM criteria for positive oropharyngeal carcinomas. Cancer, 122(13), 2021–2030.
Huang, S. H., Patel, S., O’Sullivan, B., Shen, X., Weinreb, I., Perez-Ordonez, B., et al. (2015). Longer survival in patients with human papillomavirus-related head and neck cancer after positive postradiation planned neck dissection. Head & Neck, 37(7), 946–952.
Huang, S. H., Perez-Ordonez, B., Liu, F. F., Waldron, J., Ringash, J., Irish, J., et al. (2012). Atypical clinical behavior of p16-confirmed HPV-related oropharyngeal squamous cell carcinoma treated with radical radiotherapy. International Journal of Radiation Oncology, Biology, Physics, 82(1), 276–283.
Hutcheson, K. A., Holsinger, F. C., Kupferman, M. E., & Lewin, J. S. (2015). Functional outcomes after TORS for oropharyngeal cancer: A systematic review. European Archives of Otorhinolaryngology, 272(2), 463–471.
Jemal, A., Simard, E. P., Dorell, C., Noone, A. M., Markowitz, L. E., Kohler, B., et al. (2013). Annual report to the nation on the status of cancer, 1975–2009, featuring the burden and trends in human papillomavirus (HPV)-associated cancers and HPV vaccination coverage levels. Journal of the National Cancer Institute, 105(3), 175–201.
Kaka, A. S., Kumar, B., Kumar, P., Wakely, P. E., Jr., Kirsch, C. M., Old, M. O., et al. (2013). Highly aggressive HPV-related oropharyngeal cancer: Clinical, radiologic, and pathologic characteristics. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 116(3), 327–335.
Kamerow, D. (2016). HPV vaccine: Effective but underused in the US. British Medical Journal, 353, i2060. https://doi.org/10.1136/bmj.12060. (Published 14 April 2016).
Khariwala, S. S., Moore, M. G., Malloy, K. M., Gosselin, B., & Smith, R. V. (2015). The “HPV Discussion”: Effective use of data to deliver recommendations to patients impacted by HPV. Otolaryngology - Head and Neck Surgery, 153(2), 518–525.
Kharytaniuk, N., Molony, P., Boyle, S., O’Leary, G., Werner, R., Heffron, C., et al. (2016). Association of extracapsular spread with survival according to human papillomavirus status in oropharyngeal squamous cell carcinoma and carcinoma of the unknown primary site. JAMA Otolaryngology - Head and Neck Surgery, 142(7), 683–690.
Khwaia, S. S., Baker, C., Haynes, W., Spencer, C. R., Gay, H., Thorstad, W., et al. (2016). High E6 gene expression predicts for distant metastasis and poor survival in patients with HPV-positive oropharyngeal squamous cell carcinoma. International Journal Radiation Oncology, Biology, Physics, 95(4), 1132–1141.
Kliewer, E. V., Demers, A. A., Elliott, L., Lotocki, R., Butler, J. R., & Brisson, M. (2009). Twenty-year trends in the incidence and prevalence of diagnoses anogenital warts in Canada. Sexually Transmitted Diseases, 36(6), 380–386.
Kreimer, A. R., Bhatia, R. K., Messeguer, A. L., Gonzalez, P., Herrero, R., & Giuliano, A. R. (2010). Oral human papillomavirus in health individuals: A systematic review of the literature. Sexually Transmitted Diseases, 37, 386–391.
Kreimer, A. R., Clifford, G. M., Boyle, P., & Franceschi, S. (2005). Human papillomavirus types in head and neck squamous cell carcinomas worldwide: A systematic review. Cancer Epidemiology, Biomarkers & Prevention, 14(2), 467–475.
Kreimer, A. R., Johansson, M., Waterboer, T., Kaaks, R., Chang-Claude, J., Drogen, D., et al. (2013). Evaluation of human papillomavirus antibodies and risk of subsequent head and neck cancer. Journal of Clinical Oncology, 31(21), 2708–2715.
Kreimer, A. R., Pierce Campbell, C. M., Lin, H. Y., Fulp, W., Papenfuss, M. R., Abrahamsen, M., et al. (2013). Incidence and clearance of oral human papillomavirus infection in men: The HIM cohort study. Lancet, 382, 877–887.
Kubicek, G. J., Champ, C., Fogh, S., Wang, F., Reddy, E., Intenzo, C., et al. (2010). FDG-PET staging and important of lymph node SUV in head and neck cancer. Head and Neck Oncology, 2, 19.
Kugaya, A., Akechi, T., Okuyama, T., Nakano, T., Mikami, I., Okamura, H., et al. (2000). Prevalence, predictive factors, and screening for psychologic distress in patients with newly diagnosed head and neck cancer. Cancer, 88, 2817–2223.
Kumar, B., Cordell, K., Lee, J., Worden, F. P., Prince, M. D., Tran, H. H., et al. (2008). EGFR, p16, HPV titer Bcl-xL, and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer. Journal of Clinical Oncology, 26(19), 3128–3137.
Lacchetti, C., Waldron, J., Perez-Ordonez, B., Kamel-Reid, S., Cripps, C., & Gilbert, R. (2013). Routine HPV testing in HNSCC (program in evidence-based care evidence-based series no. 5–9). Toronto, ON: Cancer Care Ontario.
Lassen, P., Eriksen, J. G., Hamilton-Dutoit, S., Tramm, T., Alsner, J., & Overgaard, J. (2009). Effect of HPV-associated p16INK4A expression on response to radiotherapy and survival in squamous cell carcinoma of the head and neck. Journal of Clinical Oncology, 27, 1992–1998.
Lee, L. A., Huang, C. G., Liao, C. T., Lee, L. Y., Hsueh, C., Chen, T. C., et al. (2012). Human papillomavirus-16 infection in advanced oral cavity cancer patients is related to an increased risk of distant metastases and poor survival. PLoS One, 7(7), e40767. https://doi.org/10.1371/journal.pone.0040767
Lin, B. M., Wang, H., D’Souza, G., Zhang, Z., Fakhry, C., Joseph, A. W., et al. (2013). Long-term prognosis and risk factors among patients with HPV-associated oropharyngeal squamous cell carcinoma. Cancer, 119(9), 3462–3472.
Lindel, K., Beer, K. T., Laissue, J., Greiner, R. H., & Aebersold, D. M. (2001). Human papillomavirus positive squamous cell carcinoma of the oropharynx a radiosensitive subgroup of head and neck carcinoma. Cancer, 92(4), 805–813.
Loning, T., Ikenberg, H., Becker, J., Gissmann, L., Hoepfer, I., & zur Hausen, H. (1985). Analysis of oral papillomas, leukoplakias, and invasive carcinomas for human papillomavirus type related DNA. The Journal of Investigative Dermatology, 84(5), 417–420.
Louvanto, K., Rautava, J., Willberg, J., Wideman, L., Syrjänen, K., Grénman, S., et al. (2013). Genotype-specific incidence and clearance of human papillomavirus in oral mucosa of women: A six-year follow-up study. PLoS One, 8, e53413. https://doi.org/10.1371/journal.pone.0053413
Lydiatt, W. M., Patel, S. G., O’Sullivan, B., Brandwein, M. S., Ridge, J. A., Migliacci, J. C., et al. (2017). Head and neck cancers – major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA: A Cancer Journal for Clinicians, 67, 122–137.
Machtay, M., Moughan, J., Trotti, A., Garden, A. S., Weber, R. S., Cooper, J. S., et al. (2008). Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: An RTOG analysis. Journal of Clinical Oncology, 26(21), 3582–3589.
Markowitz, L. E., Liu, G., Hariri, S., Steinau, M., Dunne, E. F., & Unger, E. R. (2016). Prevalence of HPV after introduction of the vaccination program in the United States. Pediatrics, 137, 1–9.
Masterson, L., Moualed, D., Masood, A., Dwivedi, R. C., Benson, R., Sterling, J. C., et al. (2014). De-escalation treatment protocols for human papillomavirus-associated oropharyngeal squamous cell carcinoma. The Cochrane Database of Systematic Reviews, 15(2). https://doi.org/10.1002/14651858.CD010271.pub2
Maxwell, J. H., Ferris, R. L., Gooding, W., Cunningham, D., Mehta, V., Kim, S., et al. (2013). Extracapsular spread in head and neck carcinoma: Impact of site and human papillomavirus status. Cancer, 119(18), 3302–3308.
Maxwell, J. H., Kumar, B., Feng, F., Worden, F. P., Lee, J., Eisbruch, A., et al. (2012). Tobacco use in HPV-positive advanced oropharynx cancer patients related to increased risk of distant metastases and tumor recurrence. Clinical Cancer Research, 16(4), 1226–1235.
Maxwell, J. H., Mehta, V., Wang, H., Cunningham, D., Duvvuri, U., Kim, S., et al. (2014). Quality of life in head and neck cancer patients: Impact of HPV and primary treatment modality. Laryngoscope, 124(7), 1592–1597.
McIlwain, W. R., Sood, A. J., Nguyen, S. A., & Day, T. A. (2014). Initial symptoms in patients with HPV-positive and HPV-negative oropharyngeal cancer. JAMA Otolaryngology - Head and Neck Surgery, 140(5), 441–447.
McQuillan, G., Kruszon-Moran, D., Markowitz, L. E., Unger, E. R., & Paulose-Ram, R. (2017). Prevalence of HPV in adults aged 18–69: United States, 2011–2014. NCHS Data Brief, 280, 1–8.
Mehanna, H., Beech, T., & Nicholson, T. (2013). Prevalence of human papillomavirus in oropharyngeal and non-oropharyngeal head and neck cancer – a systematic review and meta-analysis of trends by time and region. Head & Neck, 35(5), 747–755.
Mehanna, H., Franklin, N., Compton, N., Robinson, M., Powell, N., Biswas-Baldwin, N., et al. (2016). Geographic variation in human papillomavirus-related oropharyngeal cancer: Data from 4 multinational randomized trials. Head & Neck, 38(Suppl1), E1863–E1869.
Milbury, K., Rosenthal, D. I., El-Naggar, A., & Badr, H. (2013). An exploratory study of the informational and psychosocial needs of patients with human papillomavirus-associated oropharyngeal cancer. Oral Oncology, 49(11), 1067–1071.
Mundi, N., Theurer, J., Warner, A., Yoo, J., Fung, K., MacNeil, D., … Nichols, A. C. (2018). The impact of seasonal operating room closures on wait times for oral cancer surgery. Current Oncology, 25(1), 67.
Naik, M., Ward, M. C., Bledsoe, T. J., Kumar, A. M. S., Rybicki, L. A., Saxton, J. P., et al. (2015). It is not just IMRT: Human papillomavirus related oropharynx squamous cell carcinoma is associated with better swallowing outcomes after definitive chemoradiotherapy. Oral Oncology, 51, 800–804.
National Comprehensive Cancer Network. (n.d.). About the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines (R)). Retrieved August 17, 2017, from https://www.nccn.org/professionals/default.aspx.
Nichols, A. C., Palma, D. A., Dhaliwal, S. S., Tan, S., Theurer, J., Chow, W., et al. (2013). The epidemic of human papillomavirus and oropharyngeal cancer in a Canadian population. Current Oncology, 20(4), 212–219.
Niedobitek, G., Pitteroff, S., Herbst, H., Shepherd, P., Finn, T., Anagnostopoulos, I., et al. (1990). Detection of human papillomavirus type 16 DNA in carcinomas of the palatine tonsil. Journal of Clinical Pathology, 43(11), 918–921.
Nien, H. H., Sturgis, E. M., Kies, M. S., El-Naggar, A. K., Morrison, W. H., Beadle, B. M., et al. (2016). Comparison of systemic therapies used concurrently with radiation for the treatment of human papillomavirus-associated oropharyngeal cancer. Head & Neck, 38(Suppl1), E1554–E1561.
O’Rorke, M. A., Ellison, M. V., Murray, L. J., Moran, M., James, J., & Anderson, L. A. (2012). Human papillomavirus related head and neck cancer survival: A systematic review and meta-analysis. Oral Oncology, 48(12), 1191–1201.
O’Sullivan, B., Huang, S. H., Siu, L. L., Waldron, J., Zhao, H., Perez-Ordonez, B., et al. (2013). Deintensification candidate subgroups in human papillomavirus-related oropharyngeal cancer according to minimal risk of distant metastasis. Journal of Clinical Oncology, 31(5), 543–550.
O’Sullivan, D., Huang, S. H., Su, J., Garden, A. S., Sturgis, E. M., Dahlstrom, K., et al. (2016). Development and validation of a staging system for HPV-related oropharyngeal cancer by the International Collaboration on Oropharyngeal cancer Network for Staging (ICON-S): A multicenter cohort study. Lancet Oncology, 17(4), 440–451.
Palma, D. (2017). Taking charge of cancer: What you need to know to get the best treatment. Oakland, CA: New Harbinger Publications.
Parsons, J. T., Mendenhall, W. M., Stringer, S. P., Amdur, R. J., Hinerman, R. W., Villaret, D. B., et al. (2002). Squamous cell carcinoma of the oropharynx: Surgery, radiation therapy, or both. Cancer, 94(11), 2967–2980.
Paz, I. B., Cook, N., Odom-Maryon, T., Xie, Y., & Wilczynski, S. P. (1997). Human papillomavirus (HPV) in head and neck cancer: An association of HPV 16 with squamous cell carcinoma of Waldeyer’s tonsillar ring. Cancer, 79(3), 595–604.
Pickard, R. K. L., Xiao, W., Broutian, T. R., He, X., & Gillison, M. L. (2012). The prevalence and incidence of oral human papillomavirus infection among young men and women, aged 18-30 years. Sexually Transmitted Diseases, 39, 559–566.
Pignon, J. P., le Maître, A., Maillard, E., Bourhis, J., & MACH-NC Collaborative Group. (2009). Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 93 randomised trials and 17,346 patients. Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology, 92(1), 4–14.
Posner, M. R., Lorch, J. H., Goloubeva, O., Tan, M., Schumaker, L. M., Sarlis, N. J., et al. (2011). Survival and human papillomavirus in oropharynx cancer in TAX 324: A subset analysis from an international phase III trial. Annals of Oncology, 22(5), 1071–1077.
Proceddu, S. V. (2016). A TNM classification for HPV+ oropharyngeal cancer. Lancet Oncology, 17(4), 403–404.
Ramer, I., Varier, I., Zhang, D., Demicco, E. G., Posner, M. R., Misiukiewicz, K., et al. (2016). Racial disparities in incidence of human papillomavirus-associated oropharyngeal cancer in an urban population. Cancer Epidemiology, 44, 91–95.
Rautava, J., Willberg, J., Louvanto, K., Wideman, L., Syrjanen, K., Grenman, S., et al. (2012). Prevalence, genotype distribution and persistence of human papillomavirus in oral mucosa of women: A six-year follow-up study. PLoS One, 7(8), e42171. https://doi.org/10.1371/journal.pone.0042171
Rettig, E., Keiss, A. P., & Fakhry, C. (2015). The role of sexual behavior in head and neck cancer: Implications for prevention and therapy. Expert Review of Anticancer Therapy, 15(1), 35–49.
Ringash, J. (2015). Survivorship and quality of life in head and neck cancer. Journal of Clinical Oncology, 33(29), 3322–3327.
Ringash, J., Fisher, R., Peters, L., Trotti, A., O’Sullivan, B., Corry, J., et al. (2016). Effect of p16 status on the quality-of-life experience during chemoradiation for locally advanced oropharyngeal cancer: A substudy of randomized trial trans-tasman radiation oncology group (TROG) 02.02 (HeadSTART). International Journal of Radiation Oncology, Biology, Physics, 97(4), 678–686.
Rodriguez, C. P., Adelstein, D. J., Rybicki, L. A., Savvides, P., Saxton, J. P., Koyfman, S. A., et al. (2015). Randomizes phase III study of 2 cisplatin-based chemoradiation regimens in locally advanced head and neck squamous cell carcinoma: Impact of changing disease epidemiology on contemporary trial design. Head & Neck, 37(11), 1583–1589.
Salazar, C. R., Smith, R. V., Garg, M. K., Haigentz, M., Jr., Schiff, B. A., Kawachi, N., et al. (2014). Human papillomavirus-associated head and neck squamous cell carcinoma survival: A comparison by tumor site and initial treatment. Head and Neck Pathology, 8(1), 77–87.
Samuels, S. E., Tao, Y., Lyden, T., Haxer, M., Spector, M., Malloy, K. M., et al. (2016). Comparisons of dysphagia and quality of life (QOL) in comparable patients with HPV-positive oropharyngeal cancer receiving chemo-irradiation or cetuximab-irradiation. Oral Oncology, 54, 68–74.
Sasieni, P., Castanon, A., & Cuzick, J. (2009). Effectiveness of cervical screening with age: Population based case-control study of prospectively recorded data. British Medical Journal, 339, b2968. https://doi.org/10.1136/bmj.b2968
Schache, A. G., Powell, N. G., Cuschieri, K. S., Robinson, M., Leary, S., Mehanna, H., et al. (2016). HPV-related oropharynx cancer in the United Kingdom: An evolution in the understanding of disease etiology. Cancer Research, 76(22), 6598–6606.
Schlecht, N. F., Brandwein-Gensler, M., Nuovo, G. J., Li, M., Dunne, A., Kawachi, N., et al. (2011). A comparison of clinically utilized human papillomavirus detection methods in head and neck cancer. Modern Pathology: An Official Journal of the United States and Canadian Academy of Pathology, Inc, 24(10), 1295–1305.
Schwartz, S. M., Daling, J. R., Doody, D. R., Wipf, G. C., Carter, J. J., Madeleine, M. M., et al. (1998). Oral cancer risk in relation to sexual history and evidence of human papillomavirus infection. Journal of the National Cancer Institute, 90(21), 1626–1636.
Seiwert, T. (2013). Accurate HPV testing: A requirement for precision medicine for head and neck cancer. Annals of Oncology, 24(11), 2711–2713.
Sharma, A., Mendez, E., Yueh, B., Lohavanichbutr, P., Houck, J., Doody, D. R., et al. (2012). Human papillomavirus-positive oral cavity and oropharyngeal cancer patients do not have better quality-of-life trajectories. Otolaryngology - Head and Neck Surgery, 146(5), 739–745.
Sinha, P., Lewis, J. S., Jr., Piccirillo, J. F., Kallogieri, D., & Haughey, B. H. (2012). Extracapsular spread and adjuvant therapy in human papillomavirus-related, p16-positive oropharyngeal carcinoma. Cancer, 118(14), 3519–3530.
Sinha, P., Pipkorn, P., Thorstad, W. L., Gay, H. A., & Haughey, B. H. (2016). Does elimination of planned postoperative radiation to the primary bed in p16-positive, transorally-resected oropharyngeal carcinoma associate with poorer outcomes? Oral Oncology, 61, 127–134.
Sinha, P., Thorstad, W. T., Nussenbaum, B., Haughey, B. H., Adkins, D. R., Kallogieri, D., et al. (2014). Distant metastasis in p16-positive oropharyngeal squamous cell carcinoma: A critical analysis of patterns and outcomes. Oral Oncology, 50(1), 45–51.
Snijders, P. J., Cromme, F. V., van den Brule, A. J., Schrijnemakers, H. F., Snow, G. B., Meijer, C. J., et al. (1992). Prevalence and expression of human papillomavirus in tonsillar carcinomas, indicating a possible viral etiology. International Journal of Cancer, 51(6), 845–850.
Spanos, W. C., Nowicki, P., Lee, D. W., Hoover, A., Hostager, B., Gupta, A., et al. (2009). Immune response during therapy with cisplatin or radiation for human papillomavirus-related head and neck cancer. Archives of Otolaryngology - Head and Neck Surgery, 135(11), 1137–1146.
Spector, M. E., Gallagher, K. K., Light, E., Ibrahim, M., Chanowski, E. J., Moyer, J. S., et al. (2012). Matted nodes: Poor prognostic marker in oropharyngeal squamous cell carcinoma independent of HPV and EGFR status. Head & Neck, 34(12), 1727–1733.
Stokley, S., Jeyarajah, J., Yankey, D., Cano, M., Gee, J., Roark, J., et al. (2014). Human papillomavirus vaccination coverage among adolescents, 2007–2013, and postlicensure vaccine safety monitoring, 2006–2014 – United States. Morbidity and Mortality Weekly Report, 63, 620–624.
Stransky, N., Egloff, A. M., Tward, A. D., Kostic, A. D., Cibulskis, K., Sivachenko, A., et al. (2011). The mutation landscape of head and neck squamous cell carcinoma. Science, 333(6046), 1157–1160.
Syrjänen, K. J., Syrjänen, S. M., Lamberg, M. A., & Pyrhönen, S. (1983). Human papillomavirus (HPV) involvement in squamous cell lesions of the oral cavity. Proceedings of the Finnish Dental Society, 79(1), 1–8.
Taberna, M., Resteghini, C., Swanson, B., Pickard, R. K. L., Jiang, B., Xiao, W., et al. (2016). Low etiologic fraction for human papillomavirus in larynx squamous cell carcinoma. Oral Oncology, 61, 55–61.
Thavaraj, S., Stokes, A., Guerra, E., Bibel, J., Halligan, E., Long, A., et al. (2011). Evaluation of human papillomavirus testing for squamous cell carcinoma of the tonsil in clinical practice. Journal of Clinical Pathology, 64(4), 308–312.
Trosman, S. J., Koyfman, S. A., Ward, M. C., Al-Khudari, S., Nwizu, T., Greskovich, J. F., et al. (2015). Effect of human papillomavirus on patterns of distant metastatic failure in oropharyngeal squamous cell carcinoma treated with chemoradiotherapy. JAMA Otolaryngology – Head and Neck Surgery, 141(5), 457–462.
Truong Lam, M., O’Sullivan, B., Gullane, P., & Hui Huang, S. (2016). Challenges in establishing the diagnosis of human papillomavirus-related oropharyngeal carcinoma. Laryngoscope, 126, 2270–2275.
Urban, D., Corry, J., & Rischin, D. (2014). What is the best treatment for patients with human papillomavirus-positive and –negative OPSCC? Cancer, 120(10), 1462–1470.
van Harten, M. C., Hoebers, F. J. P., Kross, K. W., van Werkhoven, E. D., van den Brekel, M. W. M., & van Dijk, B. A. C. (2015). Determinants of treatment waiting times for head and neck cancer in the Netherlands and their relation to survival. Oral Oncology, 51(3), 272–278.
Veterans Affairs Laryngeal Cancer Study Group. (1991). Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. New England Journal of Medicine, 324(24), 1685–1690.
Vicus, D., Sutradhar, R., Lu, Y., Elit, L., Kupets, R., Paszat, L., et al. (2014). The association between cervical cancer screening and mortality from cervical cancer: A population based case-control study. Gynecologic Oncology, 133, 167–171.
Ward, G., Mehta, V., & Moore, M. (2016). Morbidity, mortality and cost from HPV-related oropharyngeal cancer: Impact of 2-, 4-, and 9-valent vaccines. Human Vaccines & Immunotherapies, 12(6), 1343–1347.
Worsham, M. J., Stephen, J. K., Chen, K. M., Mahan, M., Schweitzer, V., Havard, S., et al. (2013). Improved survival with HPV among African Americans with oropharyngeal cancer. Clinical Cancer Research, 19(9), 2486–2492.
Xiao, C., Zhang, Q., Nquyen-Tan, P. F., List, M., Weber, R. S., Ang, K. K., et al. (2017). Quality of life and performance status from a substudy conducted within a prospective phase 3 randomized trial of concurrent standard radiation versus accelerated radiation plus cisplatin for locally advanced head and neck carcinoma: NRG Oncology RTOG 0129. International Journal of Radiation Oncology, Biology, Physics, 97(4), 667–677.
Zafereo, M. E., Xu, L., Dahlstrom, K. R., Viamonte, C. A., El-Naggar, A. K., Wei, Q., et al. (2016). Squamous cell carcinoma of the oral cavity often overexpresses p16 but is rarely driven by human papillomavirus. Oral Oncology, 56, 47–53.
zur Hausen, H. (1976). Condylomata acuminata and human genital cancer. Cancer Research, 36(2 pt 2), 794.
zur Hausen, H. (1982). Human genital cancer: Synergism between two virus infections or synergism between a virus infection and initiating events. Lancet, 2(8312), 1370–1372.
zur Hausen, H. (2009). Papillomavirus in the causation of human cancers – a brief historical account. Virology, 384(2), 260–265.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Theurer, J.A. (2019). Human Papillomavirus-Related Head and Neck Cancer. In: Doyle, P. (eds) Clinical Care and Rehabilitation in Head and Neck Cancer. Springer, Cham. https://doi.org/10.1007/978-3-030-04702-3_4
Download citation
DOI: https://doi.org/10.1007/978-3-030-04702-3_4
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-04701-6
Online ISBN: 978-3-030-04702-3
eBook Packages: MedicineMedicine (R0)